Raila Aro1, Elisa Mäkäräinen-Uhlbäck2, Noora Ämmälä3, Tero Rautio2, Pasi Ohtonen2, Juha Saarnio2, Sanna Meriläinen2. 1. Department of Surgery, Oulu University Hospital, Oulu, Finland; Division of Operative Care and Medical Research Center, Oulu University Hospital and University of Oulu, Finland. Electronic address: raila.aro@ppshp.fi. 2. Department of Surgery, Oulu University Hospital, Oulu, Finland; Division of Operative Care and Medical Research Center, Oulu University Hospital and University of Oulu, Finland. 3. Department of Surgery, Oulu University Hospital, Oulu, Finland.
Abstract
BACKGROUND: The aim of this study was to evaluate whether sarcopenia or myosteatosis have an impact on short- and long-term results in patients who were surgically treated for colorectal cancer. METHODS: During 2007-2011 curatively treated colorectal cancer patients (n = 348) were included in the study. Clinical data was collected retrospectively from patient registers. Skeletal muscle mass was measured at the L3 level via venous-phase computed tomography and patients were divided into sarcopenic and non-sarcopenic and into myosteatotic and non-myosteatotic. Postoperative morbidity and mortality were analysed in these groups. RESULTS: Sarcopenia was found in 208 patients (59.8%) and myosteatosis was found in 108 patients (31.2%). Sarcopenia was associated with increased risk of postoperative pneumonia (6.7% vs. 1.4%, p = 0.021). Sarcopenic colon cancer patients had higher rate of cardiorespiratory complications than non-sarcopenic (6.3% vs. 0.0%, p = 0.023) and sarcopenic rectum cancer patients had more often pneumonia than non-sarcopenic (8.5% vs. 0.0%, p = 0.041). Discharge to home was less common in myosteatotic patients than in non-myosteatotic patients (47.7% vs. 76.9%, p < 0.001) and also in sarcopenic patients than in non-sarcopenic patients (62.7% vs. 75.5%, p = 0.013). Myosteatotic patients had decreased overall survival according to a Kaplan-Meier analysis (p = 0.002) and in the multivariable-adjusted Cox model (HR = 1.6, p = 0.034). CONCLUSIONS: Sarcopenia increases the pneumonia and cardiorespiratory complication rates. Sarcopenia and myosteatosis predicts the need for institutional care after colorectal cancer surgery. Sarcopenia and myosteatosis seem to be negative factors for colorectal cancer patients' survival. Myosteatosis is an independent risk factor for poor overall 5-year survival.
BACKGROUND: The aim of this study was to evaluate whether sarcopenia or myosteatosis have an impact on short- and long-term results in patients who were surgically treated for colorectal cancer. METHODS: During 2007-2011 curatively treated colorectal cancerpatients (n = 348) were included in the study. Clinical data was collected retrospectively from patient registers. Skeletal muscle mass was measured at the L3 level via venous-phase computed tomography and patients were divided into sarcopenic and non-sarcopenic and into myosteatotic and non-myosteatotic. Postoperative morbidity and mortality were analysed in these groups. RESULTS:Sarcopenia was found in 208 patients (59.8%) and myosteatosis was found in 108 patients (31.2%). Sarcopenia was associated with increased risk of postoperative pneumonia (6.7% vs. 1.4%, p = 0.021). Sarcopenic colon cancerpatients had higher rate of cardiorespiratory complications than non-sarcopenic (6.3% vs. 0.0%, p = 0.023) and sarcopenic rectum cancerpatients had more often pneumonia than non-sarcopenic (8.5% vs. 0.0%, p = 0.041). Discharge to home was less common in myosteatotic patients than in non-myosteatoticpatients (47.7% vs. 76.9%, p < 0.001) and also in sarcopenic patients than in non-sarcopenicpatients (62.7% vs. 75.5%, p = 0.013). Myosteatotic patients had decreased overall survival according to a Kaplan-Meier analysis (p = 0.002) and in the multivariable-adjusted Cox model (HR = 1.6, p = 0.034). CONCLUSIONS:Sarcopenia increases the pneumonia and cardiorespiratory complication rates. Sarcopenia and myosteatosis predicts the need for institutional care after colorectal cancer surgery. Sarcopenia and myosteatosis seem to be negative factors for colorectal cancerpatients' survival. Myosteatosis is an independent risk factor for poor overall 5-year survival.
Authors: Raila Aro; Sanna Meriläinen; Päivi Sirniö; Juha P Väyrynen; Vesa-Matti Pohjanen; Karl-Heinz Herzig; Tero T Rautio; Elisa Mäkäräinen; Reetta Häivälä; Kai Klintrup; Markus J Mäkinen; Juha Saarnio; Anne Tuomisto Journal: J Clin Med Date: 2022-05-09 Impact factor: 4.964
Authors: Susanna Niemeläinen; Heini Huhtala; Esa Jämsen; Jyrki Kössi; Jan Andersen; Anu Ehrlich; Eija Haukijärvi; Suvi Koikkalainen; Selja Koskensalo; Anne Mattila; Tarja Pinta; Mirjami Uotila-Nieminen; Hanna Vihervaara; Marja Hyöty Journal: BJS Open Date: 2022-07-07